This resource provides Good Manufacturing Practice (GMP)-quality candidate vaccine viruses for zoonotic influenza, a critical component of global influenza pandemic preparedness. Candidate vaccine viruses have been used to create H5, H9, and H7 vaccine lots that have been deployed to national stockpiles and/or clinical trials.

The WRCEVA program maintains the Emerging Viruses and Arboviruses Reference Collection and provides reagents and support for investigations of virus outbreaks throughout the world. 

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

This free resource offers easy searching of experimental data characterizing antibody and T cell epitopes studied in humans, non-human primates, and other animal species.

Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Note: Devices are excluded.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

The ChemDB database contains information extracted from scientific literature on the structure and activity of compounds that have been tested against HIV, opportunistic pathogens, and TB. This database is continually updated with information extracted from published literature, including the chemical structure and biological activity of compounds.

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB. Each Core Laboratory Group is comprised of several Specialty Laboratories that provide a broad range of assays and services required to conduct the scientific agenda of the ACTG and to complement laboratory services, and where appropriate, with that of other DAIDS-sponsored HIV/AIDS clinical trials networks.

The specimen repositories are a collaboration between the ACTG and IMPAACT clinical trial networks to make the large body of specimens collected for HIV research available to investigators.

The specimens stored at the repositories were initially collected for specific studies that have concluded, and are now available to investigators conducting new research.